PMS-Fluconazole 50 mg Tablets Recalled by Pharmascience for Incorrect Quantity 2026

Health Canada has issued a health product recall for PMS-Fluconazole 50 mg Tablets manufactured by Pharmascience Inc., affecting lot number 662615. The recall, identified under reference number RA-82182, was initiated due to a packaging issue in which the affected batch may not contain the correct quantity of tablets. The recall reaches retailers across Canada and is classified as a Type III recall.

What Products Are Being Recalled?

The following product is subject to this recall:

• Product Name: PMS-Fluconazole 50 mg Tablets
• Brand: Pharmascience Inc.
• Drug Identification Number (DIN): 02245643
• Dosage Form: Tablet
• Strength: Fluconazole 50 mg
• Lot Number: 662615

Fluconazole is an antifungal medication commonly prescribed to treat a variety of fungal infections. Patients relying on this medication require the correct dosage to ensure proper treatment outcomes.

Why Was This Recall Issued?

The recall was initiated because the affected batch of PMS-Fluconazole 50 mg Tablets may not contain the correct quantity of tablets as labeled. This is categorized as a Health products – Packaging issue. A Type III recall classification, as defined by Health Canada, typically indicates a situation where use of or exposure to the product is not likely to cause any adverse health consequences; however, a shortage of tablets could result in incomplete treatment courses for patients.

Incomplete antifungal therapy may allow fungal infections to persist or recur, potentially leading to prolonged illness. Patients who unknowingly receive fewer tablets than prescribed may not complete their full course of treatment, undermining the effectiveness of their therapy.

Who Is Affected?

This recall affects consumers, healthcare providers, and retailers across Canada who may have dispensed or received lot number 662615 of PMS-Fluconazole 50 mg Tablets. The recall depth is at the retailer level, meaning pharmacies and other retail outlets are the focus of the corrective action. The general public, healthcare professionals, and industry stakeholders have all been identified as relevant audiences for this notice.

What Should You Do?

• Check if your product is from the affected lot number 662615 with DIN 02245643.
• Consult your healthcare provider before discontinuing use of the affected product or if you have any health concerns related to your treatment.
• Contact Pharmascience Inc. directly if you have questions about the recall. The company is located at: 6111 avenue Royalmount, suite 100, Montreal, QC H4P 2T4, Canada.
• Report any health product-related side effects to Health Canada through the MedEffect Canada adverse reaction reporting system.
• Report any other health product safety complaints to Health Canada via the designated complaints portal.

Official Statement

According to Health Canada, the recall notice states: ‘The affected batch may not contain the correct quantity of tablets.’ The recall was published on June 8, 2026, and was issued by Health Canada under recall identification number RA-82182. Pharmascience Inc. is the recalling firm responsible for this action. Consumers and healthcare providers are encouraged to verify their stock and take appropriate action as outlined above. For updates on this and other recalls, Canadians can subscribe to Health Canada recall notifications at the official recalls and safety alerts portal.